GCM
VYGR icon

Gladius Capital Management’s Voyager Therapeutics VYGR Stock Holding History

Gladius Capital Management’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-3,182
Closed -$24.7K – 421
2023
Q3 		$24.7K Buy
+3,182
New +$29.1K ﹤0.01% 331

Other funds holding VYGR

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Gladius Capital Management's VYGR Position: Q4 2023 in Review

Gladius Capital Management sold out of Voyager Therapeutics (VYGR) in Q4 2023, closing a stake of 3,182 shares — an estimated $24.7K sold.

Gladius Capital Management first reported a position in VYGR in Q3 2023 and held it in 1 quarter. The position peaked at $24.7K in Q3 2023. 107 funds tracked by Wall St. Rank hold VYGR as of Q4 2023.

  • Gladius Capital Management reported no remaining Voyager Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Gladius Capital Management sold 3,182 Voyager Therapeutics shares in Q4 2023, an estimated $24.7K.
  • Gladius Capital Management first reported a position in Voyager Therapeutics in Q3 2023 and held it in 1 quarter.
  • Gladius Capital Management's Voyager Therapeutics position peaked at $24.7K in Q3 2023.
  • 107 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q4 2023.

Based on Gladius Capital Management's 13F filing for Q4 2023, filed 7 Feb 2024.